DOI QR코드

DOI QR Code

마행감석탕의 소아 마이코플라즈마 폐렴 치료에 대한 체계적 문헌 고찰 및 메타분석

Mahaenggamsuktang for treating Mycoplasma pneumonia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials (RCTs)

  • 이유빈 (가천대학교 한의과대학 소아과학교실) ;
  • 정아람 (가천대학교 한의과대학 소아과학교실)
  • Lee, Yoo Been (Department of Pediatrics, College of Korean Medicine, Gachon University) ;
  • Jeong, Aram (Department of Pediatrics, College of Korean Medicine, Gachon University)
  • 투고 : 2020.04.25
  • 심사 : 2020.05.18
  • 발행 : 2020.05.31

초록

Objectives The purpose of this study is to evaluate efficacy and safety of Mahaenggamsuktang for treating mycoplasma pneumonia in children based on the randomized controlled trials (RCTs). Methods Literatures were searched from OASIS, KISS, NDSL, CNKI, Cochrane, Embase and Pubmed, and the search was conducted on January 29, 2020. Only RCTs published since 2000 were included. Trials comparing Mahaenggamsuktang combined with antibiotics or antibiotics treatment alone for the treatment of mycoplasma pneumonia in children were included. Results 17 trials, including 2,241 participants with mycoplasma pneumonia were included in this review. As a result of the meta-analysis, total effective rate of combination of Mahaggamsuktang and antibiotics was 1.24 times higher than that of the antibiotics alone, which was statistically significant. Symptoms with fever, lung sounds, cough, chest X-ray lesion findings, wheezing were also significantly reduced in the treatment group with Mahaenggamseoktang and antibiotics. Also, Serum CRP level was significantly lower with combination treatment. The incidence of adverse reactions was lower in the treatment group with Mahaenggamseoktang and antibiotics, but it was not statistically significant. Conclusions As a result of meta-analysis, combination treatment of Mahaenggamseoktang and antibiotics seems significantly effective for the treatment of mycoplasma pneumonia in children. In order to have a higher level of evidence for efficacy and safety of Mahaenggamsuktang in treating mycoplasma pneumonia, additional RCTs with good qualities are required.

키워드

참고문헌

  1. Lee SH, Noh SM, Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Lee BC. Clinico-epidemiologic study of mycoplasma pneumoniae pneumonia (1993 through 2003). Korean J Pediatrics. 2005;48(2):154-7.
  2. Nahm CH, Cho EY, Lee KY, Kang JH, Lee BC. A comparative study of mycoplasma pneumoniae pneumonia according to age. Pediatric Infection and Vaccine. 2005;12(2):135-9.
  3. Kim EK, Yoon YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatrics. 2015;58(5):172-7. https://doi.org/10.3345/kjp.2015.58.5.172
  4. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatrics. 2012;55(2):42-7. https://doi.org/10.3345/kjp.2012.55.2.42
  5. Ahn HS, Shin HY. Hong chang-ui pediatrics, 11st ed. Seoul: Nuraen Co. 2016:700-1.
  6. Korean Centers for Disease Control and Prevention. Guidelines for the antibioic use in children with lower respiratory tract infections. 2017:54-60.
  7. Jeon YH, Kim JH. Treatment of community-acquired pneumonia in Korean children. Allergy, Asthma & Respiratory Disease. 2017;5(4):177-84. https://doi.org/10.4168/aard.2017.5.4.177
  8. Oh HS, Kim JH. The study about the comparison of Korean-Western medicine on pneumonia. Korean J Pediatrics. 1996;10(1):125-50.
  9. Bang JK. The study on the Sanghanron(傷寒論)'s Mahanggamsuktang(麻杏甘石湯). J Oriental Medical Classics. 2012;25(1):163-71.
  10. Ryu SH, Kim OY, Park GH, Choi SW, Chae JW. A case report of a child with mycoplasma pneumonia. J Pediatr Korean Med. 2011;25(2):88-93. https://doi.org/10.7778/jpkm.2011.25.2.088
  11. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
  12. Wang HB, Ge JL, Mo D. Azithromycin combined with Chinese herbal medicine Maxingshigan decoction for the treatment 106 cases of mycoplasma pneumonia in children. Medical J Chinese People's Health. 2009;21(19):2387-9.
  13. Liao YW, Chen NG, Wu ZC. Clinical observation on treatment of 50 cases of mycoplasma pneumonia in children with modified Maxingshigan decoction. Guiding J Traditional Chinese Medicine and Pharmacy. 2011;17(11):51-2.
  14. Guo HH, Zheng DR, Lin SL. Clinical observation on integrated Chinese and Western medicine for children with mycoplasma pneumonia. J Community Med. 2014;12(05):23-5.
  15. Jiang H. Intervention of modified Maxingshigan decoction on serum inflammatory cytokines in children with mycoplasma pneumonia. Nei Mongol J Traditional Chinese Med. 2014(22):2-3.
  16. Deng MH. Treating refractory mycoplasma pneumoniae pneumonia with Maxingshigan decoction. Clinical J Chinese Med. 2015;7(07):90-1.
  17. Huang Y, Yu ZH. The effects of Maxingshigan decoction combined with azithromycin on children with mycoplasma pneumoniae and on the levels of Th17/Treg cytokines. Acta Academiae Medicinae Weifang. 2016;38(05):346-8.
  18. Liu C. Efficacy of modified Maxingshigan decoction in the treatment of 40 cases of mycoplasma pneumonia in children. Nei Mongol J Traditional Chinese Med. 2016(08):3.
  19. Fei LJ. Effect of modified Maxingshigan decoction on clinical symptoms of mycoplasma pneumonia in children. J North Pharmacy. 2017(04):144-5.
  20. Fei LJ. 42 cases of children with mycoplasma pneumonia treated with integrated Chinese and Western medicine. Forum on Traditional Chinese Med. 2017;32(03):43-4.
  21. Luo ZY, Ma DY, Li WH, Lin YS, Su XN. The effect of Haoqinmaxingshigan decoction on cellular immune function in patients with mycoplasma pneumonia. J Practical Traditional Chinese Med. 2017;33(01):2-3.
  22. Yang SZ. The effects of modified Maxingshigan decoction on mycoplasma pneumonia in children. Laboratory Medicine and Clinic. 2017;14(06):881-2.
  23. Kong XY, Lei HZ. Clinical effects of modified Maxingshigan decoction combined with azithromycin in the treatment of 45 children with mycoplasma pneumonia. Clinical Research and Practice. 2018(18):131-2.
  24. Qian CJ. Clinical study of Maxingshigan decoction combined with azithromycin in the treatment of mycoplasma pneumonia in children. J Clinical Medical Literature. 2018;5(27):174-5.
  25. Wang ZH, Sun J, Liu Y, Wang X, Wang YS. Effect of Maxing shigan decoction on the IL-17 and $TNF-{\alpha}$ in children with mycoplasma pneumoniae pneumonia. Tianjin J Traditional Chinese Med. 2018;35(06):419-21.
  26. Chen QF, Gu MY, Mao QD. Efficacy of Maxingshigan decoction combined with azithromycin in treatment of mycoplasma pneumonia in children and its effect on serum inflammatory factors. Evaluation and Analysis of Drug Use in Hospital of China. 2019;19(07):840-2.
  27. Dong SY. Effect of traditional Chinese medicine combined with azithromycin on serum inflammatory factors in children with mycoplasma pneumoniae pneumonia. J China Prescription Drug. 2019;17(10):91-2.
  28. Zhang GC, Sun XM, Chen D, Guo Q, Ren YH. The effects of azithromycin and Maxingshigan decoction on mycoplasma pneumonia in children. Henan Medical Research. 2019;28(24):4527-30.
  29. Gu JS. A case report of treating fever in children with Herba Houttuyniae injection treatment. J East-West Medicine. 2002;27(3):54-5.
  30. Kim JM, Lee CW, Ahn YT, Lee H, Kim C, Kim HW, Cho SI, An WG. Antimicrobial effect of Scutellariae Radix and its thermal stability. Korean J Oriental Physiology & Pathology. 2012;26(3):325-9.
  31. Kim HE, Min SY, Kim JH. In vitro study of anti-inflammatory and analgesic effects of Salvia Miltiorrhiza (Sm) extracts using luciferase reporter gene assay. J Korean Oriental Med. 2008;29(3):88-99.
  32. Park GB, Park YC. Effects of Mahaenggamseok-tang-gagambang on immune cells and cytokines in OVA-induced asthmatic mice. J Physiology & Pathology in Korean Medicine. 2009;23(3):590-8.
  33. Park SH, Jeong HJ, Jeong SG, Lee HG. The inhibitory effects Mahaenggamseok-tang and Platycodi Radix on the cytokines of human epitherial cells. J Kyung Hee University Medical Cental. 2001;17(2):230-41.
  34. Choi SY, Seo JH, Lee KS, Choi QT. Clinical analysis of risk factors in refractory mycoplasma pneumonia in children. Allergy, Asthma & Respiratory Disease. 2018;6(1):62-7. https://doi.org/10.4168/aard.2018.6.1.62
  35. Ji MS, Sung HS, Shim TS, Jang WR, Kim MN. Mycoplasma pneumoniae pneumonia unresponsive to macrolide treatment. Laboratory Medicine Online. 2012;2(4):226-31. https://doi.org/10.3343/lmo.2012.2.4.226